24 results
Thumbnail

D1.402 - Study of lymphocyte populations and subpopulations in patients with long-COVID with reactivation of herpesvirus type 6 infection

Thumbnail

D1.397 - Eosinophilic Pneumonia Triggered by Toxocara canis in a Patient with Kartagener Syndrome: A Case Report Highlighting Diagnostic Challenges and Interdisciplinary Management

Thumbnail

D1.398 - Retrospective study of the effect of bacterial immunotheraphy on patients with chronic respiratory diseases

Thumbnail

D1.403 - Use of ketotifen as treatment for post viral infection cough in children

Thumbnail

D1.404 - Use of inactivated polybacterial mucosal vaccine (IPMV) as part of the treatment for the reduction of recurrent acute respiratory infections

Thumbnail

D1.405 - Immunological imprinting of IgG response to RV VP1 in children of the MAS and PAPS birth cohorts

Thumbnail

D1.406 - The microbiota of the urogenital canal related to papillomavirus infection

Thumbnail

D1.422 - A service review of the complex COVID-19 vaccination service

Thumbnail

D1.425 - Familial Cold Autoinflammatory Syndrome Post COVID-19 Vaccine: A Case Report

Thumbnail

D1.423 - Listening to Urticaria Patients Through Social Media: Analyzing the Impact of the COVID-19 Pandemic

Thumbnail

D1.424 - Clinical-epidemiological profile of patients with Post-Covid syndrome followed at a medical school outpatient clinic

Thumbnail

D1.426 - Cellular immunity profile in patients with urolithiasis in the presence of post-Covid syndrome

Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Thumbnail

D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab